Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (640) 640
humans (580) 580
male (341) 341
female (290) 290
pharmacology & pharmacy (267) 267
piperazines - therapeutic use (256) 256
azabicyclo compounds (249) 249
hypnotics and sedatives - therapeutic use (232) 232
azabicyclo compounds - therapeutic use (231) 231
middle aged (229) 229
adult (226) 226
animals (187) 187
sleep initiation and maintenance disorders - drug therapy (181) 181
azabicyclo compounds - pharmacology (159) 159
aged (146) 146
piperazines - adverse effects (143) 143
hypnotics and sedatives - adverse effects (133) 133
double-blind method (124) 124
zopiclone (119) 119
insomnia (113) 113
azabicyclo compounds - adverse effects (98) 98
psychiatry (94) 94
neurosciences (90) 90
azabicyclo compounds - administration & dosage (82) 82
eszopiclone (81) 81
zolpidem (81) 81
ceftazidime - therapeutic use (80) 80
mice (80) 80
microbiology (79) 79
pyridines - therapeutic use (77) 77
treatment outcome (77) 77
piperazines - pharmacology (76) 76
anti-bacterial agents - therapeutic use (75) 75
clinical neurology (67) 67
rats (67) 67
sleep (67) 67
dose-response relationship, drug (66) 66
microbial sensitivity tests (64) 64
piperazines - administration & dosage (63) 63
benzodiazepines (62) 62
hypnotics (60) 60
young adult (59) 59
hypnotics and sedatives - pharmacology (58) 58
sleep - drug effects (58) 58
adolescent (57) 57
hypnotics and sedatives - administration & dosage (56) 56
efficacy (55) 55
drug therapy (52) 52
anti-bacterial agents - pharmacology (48) 48
azabicyclo compounds - chemistry (48) 48
azabicyclo compounds - pharmacokinetics (48) 48
infectious diseases (48) 48
pyridines - adverse effects (47) 47
double-blind (45) 45
pyrimidines - therapeutic use (44) 44
aged, 80 and over (43) 43
analysis (43) 43
clinical trials as topic (43) 43
time factors (43) 43
care and treatment (42) 42
drugs (42) 42
enterobacteriaceae (41) 41
benzodiazepines - therapeutic use (40) 40
beta-lactamase inhibitors - therapeutic use (40) 40
pharmacology (40) 40
acetamides - therapeutic use (39) 39
ceftazidime (39) 39
drug combinations (38) 38
ceftazidime - pharmacology (36) 36
medicine, general & internal (35) 35
pharmacology/toxicology (35) 35
chronic disease (34) 34
drug therapy, combination (34) 34
klebsiella-pneumoniae (34) 34
pseudomonas-aeruginosa (34) 34
safety (34) 34
abridged index medicus (33) 33
medicine & public health (33) 33
zaleplon (33) 33
article (32) 32
ceftazidime-avibactam (32) 32
rats, sprague-dawley (32) 32
research (32) 32
enterobacteriaceae - drug effects (31) 31
pharmacokinetics (31) 31
pyridines - pharmacology (31) 31
adults (30) 30
beta-lactamases - metabolism (30) 30
cross-over studies (30) 30
drug resistance, multiple, bacterial (29) 29
gram-negative bacterial infections - drug therapy (29) 29
klebsiella pneumoniae - drug effects (29) 29
pseudomonas aeruginosa - drug effects (29) 29
in-vitro activity (28) 28
piperazines - pharmacokinetics (28) 28
polysomnography (28) 28
toxicology (28) 28
avibactam (27) 27
benzodiazepines - adverse effects (27) 27
beta-lactamase inhibitors - pharmacology (27) 27
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (666) 666
German (16) 16
Russian (10) 10
French (5) 5
Dutch (2) 2
Finnish (2) 2
Danish (1) 1
Hungarian (1) 1
Japanese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Diversity-oriented synthesis yields novel multistage antimalarial inhibitors
by Kato, Nobutaka and Comer, Eamon and Sakata-Kato, Tomoyo and Sharma, Arvind and Sharma, Manmohan and Maetani, Micah and Bastien, Jessica and Brancucci, Nicolas M and Bittker, Joshua A and Corey, Victoria and Clarke, David and Derbyshire, Emily R and Dornan, Gillian L and Duffy, Sandra and Eckley, Sean and Itoe, Maurice A and Koolen, Karin M. J and Lewis, Timothy A and Lui, Ping S and Lukens, Amanda K and Lund, Emily and March, Sandra and Meibalan, Elamaran and Meier, Bennett C and McPhail, Jacob A and Mitasev, Branko and Moss, Eli L and Sayes, Morgane and Van Gessel, Yvonne and Wawer, Mathias J and Yoshinaga, Takashi and Zeeman, Anne-Marie and Avery, Vicky M and Bhatia, Sangeeta N and Burke, John E and Catteruccia, Flaminia and Clardy, Jon C and Clemons, Paul A and Dechering, Koen J and Duvall, Jeremy R and Foley, Michael A and Gusovsky, Fabian and Kocken, Clemens H. M and Marti, Matthias and Morningstar, Marshall L and Munoz, Benito and Neafsey, Daniel E and Sharma, Amit and Winzeler, Elizabeth A and Wirth, Dyann F and Scherer, Christina A and Schreiber, Stuart L
Nature, ISSN 0028-0836, 2016, Volume 538, Issue 7625, pp. 344 - 349
Antimalarial drugs have thus far been chiefly derived from two sources-natural products and synthetic drug-like compounds. Here we investigate whether... 
IN-VITRO | TRANSFER-RNA SYNTHETASE | MALARIA CONTROL | PLASMODIUM-FALCIPARUM | MULTIDISCIPLINARY SCIENCES | DRUG DISCOVERY | LIVER | TARGETS | PROTEIN-SYNTHESIS | NEXT-GENERATION | HEPATIC STAGES | Azabicyclo Compounds - pharmacology | Plasmodium falciparum - enzymology | Malaria, Falciparum - prevention & control | Male | Plasmodium falciparum - cytology | Azetidines - pharmacology | Plasmodium falciparum - drug effects | Cytosol - enzymology | Malaria, Falciparum - transmission | Liver - drug effects | Azabicyclo Compounds - chemical synthesis | Azabicyclo Compounds - therapeutic use | Female | Safety | Antimalarials - chemical synthesis | Disease Models, Animal | Life Cycle Stages - drug effects | Malaria, Falciparum - drug therapy | Azabicyclo Compounds - administration & dosage | Azetidines - adverse effects | Phenylurea Compounds - therapeutic use | Antimalarials - therapeutic use | Macaca mulatta - parasitology | Phenylalanine-tRNA Ligase - antagonists & inhibitors | Drug Discovery | Antimalarials - pharmacology | Animals | Azetidines - administration & dosage | Phenylurea Compounds - chemical synthesis | Antimalarials - administration & dosage | Azetidines - therapeutic use | Phenylurea Compounds - administration & dosage | Mice | Phenylurea Compounds - pharmacology | Liver - parasitology | Plasmodium falciparum - growth & development | Prevention | Antimalarials | Disease transmission | Health aspects | Transfer RNA | Proteins | Cytochrome | Malaria | Liver | Parasites | Kinases | Drug resistance | Drug dosages | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: Results from a randomized, controlled, double-blind, phase 3 program
by Mazuski, John E and Gasink, Leanne B and Armstrong, Jon and Broadhurst, Helen and Stone, Greg G and Rank, Douglas and Llorens, Lily and Newell, Paul and Pachl, Jan
Clinical Infectious Diseases, ISSN 1058-4838, 06/2016, Volume 62, Issue 11, pp. 1380 - 1389
Background. When combined with ceftazidime, the novel non-beta-lactam beta-lactamase inhibitor avibactam provides a carbapenem alternative against... 
phase 3 | complicated intra-abdominal infection | meropenem | ceftazidime-avibactam plus metronidazole | noninferiority | INFECTIOUS DISEASES | NXL104 | MICROBIOLOGY | II TRIAL | IMMUNOLOGY | CARBAPENEM-RESISTANT ENTEROBACTERIACEAE | IN-VITRO | PHARMACOKINETICS | PSEUDOMONAS-AERUGINOSA | Humans | Middle Aged | Male | Young Adult | Anti-Bacterial Agents - therapeutic use | Metronidazole - therapeutic use | Aged, 80 and over | Metronidazole - adverse effects | Adult | Azabicyclo Compounds - therapeutic use | Female | Anti-Bacterial Agents - adverse effects | Thienamycins - adverse effects | Azabicyclo Compounds - adverse effects | Thienamycins - therapeutic use | Thienamycins - administration & dosage | Azabicyclo Compounds - administration & dosage | Metronidazole - administration & dosage | Treatment Outcome | Intraabdominal Infections - epidemiology | Adolescent | Ceftazidime - administration & dosage | Aged | Ceftazidime - adverse effects | Anti-Bacterial Agents - administration & dosage | Intraabdominal Infections - drug therapy | Ceftazidime - therapeutic use | Usage | Care and treatment | Abscess | Clinical trials | Dosage and administration | Ceftazidime | Abdomen | Confidence intervals | Prescription drugs | Pathogens | Antibiotics | Index Medicus | and Commentaries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
by Wagenlehner, Florian M and Sobel, Jack D and Newell, Paul and Armstrong, Jon and Huang, Xiangning and Stone, Gregory G and Yates, Katrina and Gasink, Leanne B
Clinical Infectious Diseases, ISSN 1058-4838, 09/2016, Volume 63, Issue 6, pp. 754 - 762
Background. The global emergence of carbapenem-resistant Enterobacteriaceae highlights the urgent need to reduce carbapenem dependence. The phase 3 RECAPTURE... 
acute pyelonephritis | ceftazidime-avibactam | complicated urinary tract infection | INFECTIOUS DISEASES | INITIAL ANTIBIOTIC-THERAPY | ANTIMICROBIAL THERAPY | MICROBIOLOGY | IMMUNOLOGY | INTRAABDOMINAL INFECTION | CARBAPENEM-RESISTANT ENTEROBACTERIACEAE | TREATMENT OPTIONS | BACTERICIDAL ACTIVITY | PSEUDOMONAS-AERUGINOSA | LACTAMASE-PRODUCING ENTEROBACTERIACEAE | SPECTRUM BETA-LACTAMASES | KLEBSIELLA-PNEUMONIAE | Doripenem | Azabicyclo Compounds - administration & dosage | Carbapenems - administration & dosage | Humans | Middle Aged | Male | Pyelonephritis - complications | Urinary Tract Infections - complications | Urinary Tract Infections - drug therapy | Carbapenems - adverse effects | Anti-Bacterial Agents - therapeutic use | Carbapenems - therapeutic use | Ceftazidime - administration & dosage | Adult | Azabicyclo Compounds - therapeutic use | Female | Aged | Anti-Bacterial Agents - adverse effects | Ceftazidime - adverse effects | Pyelonephritis - drug therapy | Anti-Bacterial Agents - administration & dosage | Ceftazidime - therapeutic use | Drug Combinations | Azabicyclo Compounds - adverse effects | Care and treatment | Usage | Pyelonephritis | Clinical trials | Urinary tract infections | Influence | Dosage and administration | Ceftazidime | Antibiotics | Drug resistance | Drug therapy | CRE bacteria | Urinary tract diseases | Index Medicus | and Commentaries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Phase 2, dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection
by Lucasti, Christopher and Vasile, Liviu and Sandesc, Dorel and Venskutonis, Donatas and McLeroth, Patrick and Lala, Mallika and Rizk, Matthew L and Brown, Michelle L and Losada, Maria C and Pedley, Alison and Kartsonis, Nicholas A and Paschke, Amanda
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 10/2016, Volume 60, Issue 10, pp. 6234 - 6243
Relebactam (REL [MK-7655]) is a novel class A/C beta-lactamase inhibitor intended for use with imipenem for the treatment of Gram-negative bacterial... 
GRAM-NEGATIVE BACTERIA | MECHANISM | ANTIBIOTIC-RESISTANCE | NO ESKAPE | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | BETA-LACTAMASE INHIBITOR | COMBINATION | OUTBREAK | EMERGENCE | KLEBSIELLA-PNEUMONIAE | DISEASES SOCIETY | Imipenem - therapeutic use | Humans | Middle Aged | Cilastatin - pharmacokinetics | Male | Imipenem - pharmacokinetics | Young Adult | Anti-Bacterial Agents - therapeutic use | Aged, 80 and over | Adult | Azabicyclo Compounds - therapeutic use | Female | Anti-Bacterial Agents - adverse effects | Cilastatin - therapeutic use | Azabicyclo Compounds - pharmacokinetics | Drug Therapy, Combination | Bacterial Infections - microbiology | Azabicyclo Compounds - adverse effects | Double-Blind Method | Bacterial Infections - drug therapy | Intraabdominal Infections - microbiology | Azabicyclo Compounds - administration & dosage | Treatment Outcome | Adolescent | Anti-Bacterial Agents - pharmacokinetics | Aged | Anti-Bacterial Agents - administration & dosage | Intraabdominal Infections - drug therapy | Drug Combinations | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234
by Papp-Wallace, Krisztina M and Nguyen, Nhu Q and Jacobs, Michael R and Bethel, Christopher R and Barnes, Melissa D and Kumar, Vijay and Bajaksouzian, Saralee and Rudin, Susan D and Rather, Philip N and Bhavsar, Satish and Ravikumar, Tadiparthi and Deshpande, Prasad K and Patil, Vijay and Yeole, Ravindra and Bhagwat, Sachin S and Patel, Mahesh V and Van Den Akker, Focco and Bonomo, Robert A
Journal of Medicinal Chemistry, ISSN 0022-2623, 05/2018, Volume 61, Issue 9, pp. 4067 - 4086
Limited treatment options exist to combat infections caused by multidrug-resistant (MDR) Gram-negative bacteria possessing broad-spectrum β-lactamases. The... 
Azabicyclo Compounds - pharmacology | Lung - microbiology | Octanes - pharmacology | Azabicyclo Compounds - chemistry | Bridged Bicyclo Compounds - chemistry | Peritonitis - microbiology | Piperidines - pharmacology | Octanes - chemistry | Bridged Bicyclo Compounds - therapeutic use | Azabicyclo Compounds - therapeutic use | Cyclooctanes - pharmacology | beta-Lactamases - metabolism | Octanes - therapeutic use | Piperidines - chemistry | Bridged Bicyclo Compounds - pharmacology | beta-Lactamase Inhibitors - pharmacology | Cyclooctanes - therapeutic use | Drug Synergism | Gram-Negative Bacteria - drug effects | beta-Lactams - pharmacology | Animals | Piperidines - therapeutic use | Lung - drug effects | beta-Lactamase Inhibitors - therapeutic use | Cyclooctanes - chemistry | Mice | Peritonitis - drug therapy | beta-Lactamase Inhibitors - chemistry | beta-Lactam Resistance - drug effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections
by Shields, Ryan K and Potoski, Brian A and Haidar, Ghady and Hao, Binghua and Doi, Yohei and Chen, Liang and Press, Ellen G and Kreiswirth, Barry N and Clancy, Cornelius J and Nguyen, M Hong
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, ISSN 1058-4838, 12/2016, Volume 63, Issue 12, pp. 1615 - 1618
Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30... 
carbapenem-resistant Enterobacteriaceae | Klebsiella pneumoniae carbapenemase | ceftazidime-avibactam resistance | INFECTIOUS DISEASES | BACTEREMIA | MICROBIOLOGY | BETA-LACTAMASES | IMMUNOLOGY | KLEBSIELLA-PNEUMONIAE | Humans | Middle Aged | Drug Resistance, Bacterial | Male | Treatment Outcome | Carbapenem-Resistant Enterobacteriaceae | beta-Lactamase Inhibitors - adverse effects | beta-Lactamase Inhibitors - therapeutic use | Adult | Azabicyclo Compounds - therapeutic use | Female | Aged | Retrospective Studies | Ceftazidime - adverse effects | Ceftazidime - therapeutic use | Azabicyclo Compounds - adverse effects | Enterobacteriaceae Infections - drug therapy | Drug resistance in microorganisms | Enterobacteriaceae infections | Enterobacter | Analysis | Dosage and administration | Research | Drug therapy | Ceftazidime | Enterobacteriaceae | Survival analysis | Drug resistance | Toxicity | CRE bacteria | Clinical outcomes | Index Medicus | Brief Reports
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms
by Temkin, Elizabeth and Torre-Cisneros, Julian and Beovic, Bojana and Benito, Natividad and Giannella, Maddalena and Gilarranz, Raúl and Jeremiah, Cameron and Loeches, Belén and MacHuca, Isabel and Jiménez-Martín, María José and Martínez, José Antonio and Mora-Rillo, Marta and Navas, Enrique and Osthoff, Michael and Pozo, Juan Carlos and Ramos, Juan Carlos Ramos and Rodriguez, Marina and Sánchez-García, Miguel and Viale, Pierluigi and Wolff, Michel and Carmeli, Yehuda
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 02/2017, Volume 61, Issue 2
Ceftazidime-avibactam (CAZ-AVI) is a recently approved beta-lactam-beta-lactamase inhibitor combination with the potential to treat serious infections caused... 
Ceftazidime-avibactam | Carbapenem resistance | Case series | EFFICACY | case series | SAFETY | MICROBIOLOGY | PLUS METRONIDAZOLE | ceftazidime-avibactam | COMBINATION | carbapenem resistance | COLISTIN-RESISTANT | BACTEREMIA | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | BLOOD-STREAM INFECTIONS | KLEBSIELLA-PNEUMONIAE | ENTEROBACTERIACEAE | Azabicyclo Compounds - pharmacology | Klebsiella pneumoniae - drug effects | Ceftazidime - pharmacology | Enterobacteriaceae - pathogenicity | Humans | Middle Aged | Salvage Therapy | Male | Pseudomonas aeruginosa - drug effects | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Klebsiella oxytoca - pathogenicity | Carbapenems - pharmacology | Carbapenems - therapeutic use | Pseudomonas aeruginosa - pathogenicity | Klebsiella pneumoniae - pathogenicity | Enterobacteriaceae - drug effects | Azabicyclo Compounds - therapeutic use | Female | Aged | Anti-Bacterial Agents - pharmacology | Ceftazidime - therapeutic use | Klebsiella oxytoca - drug effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text In vitro susceptibility of global surveillance isolates of Pseudomonas aeruginosa to ceftazidime-avibactam (INFORM 2012 to 2014)
by Nichols, Wright W and De Jonge, Boudewijn L. M and Kazmierczak, Krystyna M and Karlowsky, James A and Sahm, Daniel F
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 08/2016, Volume 60, Issue 8, pp. 4743 - 4749
Broth microdilution antimicrobial susceptibility testing was performed for ceftazidime-avibactam and comparator agents against 7,062 clinical isolates of... 
US MEDICAL-CENTERS | INHIBITION | EFFICACIES | NXL104 | RESISTANCE | BETA-LACTAM ANTIBIOTICS | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | LUNG INFECTION | COMBINATION | AZTREONAM | ENTEROBACTERIACEAE | Pseudomonas Infections - drug therapy | Humans | Africa | Pseudomonas aeruginosa - drug effects | Latin America | Middle East | Anti-Bacterial Agents - therapeutic use | beta-Lactams - pharmacology | Amikacin - therapeutic use | Asia | Azabicyclo Compounds - therapeutic use | Colistin - therapeutic use | Microbial Sensitivity Tests - methods | Ceftazidime - therapeutic use | Thienamycins - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia
by Shields, Ryan K and Nguyen, M. Hong and Chen, Liang and Press, Ellen G and Potoski, Brian A and Marini, Rachel V and Doi, Yohei and Kreiswirth, Barry N and Clancy, Cornelius J
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 08/2017, Volume 61, Issue 8
There are no data comparing outcomes of patients treated with ceftazidime-avibactam versus comparators for carbapenem-resistant Enterobacteriaceae infections.... 
Carbapenem-resistant Enterobacteriaceae | Klebsiella pneumoniae carbapenemase | Clinical success | Ceftazidime-avibactam | Bacteremia | Klebsiella pneumoniae | carbapenem-resistant Enterobacteriaceae | MORTALITY | INFECTIONS | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | ceftazidime-avibactam | bacteremia | clinical success | ENTEROBACTERIACEAE | Klebsiella pneumoniae - isolation & purification | Klebsiella Infections - drug therapy | Klebsiella pneumoniae - drug effects | Humans | Middle Aged | Bacteremia - drug therapy | Male | Treatment Outcome | Klebsiella Infections - microbiology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Carbapenems - therapeutic use | Drug Resistance, Multiple, Bacterial | beta-Lactamase Inhibitors - therapeutic use | Aged, 80 and over | Adult | Azabicyclo Compounds - therapeutic use | Bacterial Proteins - metabolism | Female | Aged | Retrospective Studies | beta-Lactamases - metabolism | Carbapenem-Resistant Enterobacteriaceae - drug effects | Ceftazidime - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections
by King, Madeline and Heil, Emily and Kuriakose, Safia and Bias, Tiffany and Huang, Vanthida and El-Beyrouty, Claudine and McCoy, Dorothy and Hiles, Jon and Richards, Lynette and Gardner, Julianne and Harrington, Nicole and Biason, Kenneth and Gallagher, Jason C
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 07/2017, Volume 61, Issue 7
Ceftazidime-avibactam is a novel cephalosporin-beta-lactamase inhibitor combination that is active against many carbapenem-resistant Enterobacteriaceae (CRE).... 
Carbapenemase | Antibiotic resistance | Beta-lactamases | MEROPENEM | EFFICACY | antibiotic resistance | SAFETY | BACTEREMIA | DOUBLE-BLIND | beta-lactamases | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | PLUS METRONIDAZOLE | carbapenemase | Hospital Mortality | Enterobacteriaceae - pathogenicity | Humans | Cephalosporins - therapeutic use | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Carbapenems - therapeutic use | Carbapenem-Resistant Enterobacteriaceae - pathogenicity | Drug Resistance, Multiple, Bacterial | beta-Lactamase Inhibitors - therapeutic use | Enterobacteriaceae - drug effects | Azabicyclo Compounds - therapeutic use | Retrospective Studies | Carbapenem-Resistant Enterobacteriaceae - drug effects | Ceftazidime - therapeutic use | Enterobacteriaceae Infections - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Antimicrobial Activity of Ceftazidime-Avibactam against Gram-Negative Organisms Collected from U.S. Medical Centers in 2012
by Helio S. Sader and Mariana Castanheira and Robert K. Flamm and David J. Farrell and Ronald N. Jones
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 03/2014, Volume 58, Issue 3, pp. 1684 - 1692
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
HOSPITALS REPORT | BETA-LACTAMASE | ANTIBACTERIAL ACTIVITY | PSEUDOMONAS-AERUGINOSA | NXL104 | SURVEILLANCE PROGRAM | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | PHARMACOKINETIC PROPERTIES | IN-VITRO ACTIVITY | KLEBSIELLA-PNEUMONIAE | ENTEROBACTERIACEAE | Azabicyclo Compounds - pharmacology | United States - epidemiology | Enterobacter cloacae - drug effects | Klebsiella pneumoniae - drug effects | Ceftazidime - pharmacology | Azabicyclo Compounds - administration & dosage | Escherichia coli - drug effects | Humans | Drug Resistance, Bacterial | Gram-Negative Bacterial Infections - drug therapy | Pseudomonas aeruginosa - drug effects | Acinetobacter - drug effects | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Gram-Negative Bacteria - drug effects | Ceftazidime - administration & dosage | Enterobacteriaceae - drug effects | Azabicyclo Compounds - therapeutic use | Anti-Bacterial Agents - pharmacology | Anti-Bacterial Agents - administration & dosage | Ceftazidime - therapeutic use | Drug Combinations | Index Medicus | Epidemiology and Surveillance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections
by Sims, Matthew and Mariyanovski, Valeri and McLeroth, Patrick and Akers, Wayne and Lee, Yu-Chieh and Brown, Michelle L and Du, Jiejun and Pedley, Alison and Kartsonis, Nicholas A and Paschke, Amanda
Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 09/2017, Volume 72, Issue 9, pp. 2616 - 2626
Objectives: The b-lactamase inhibitor relebactam can restore imipenem activity against imipenem nonsusceptible pathogens. Methods: To explore relebactam's... 
INFECTIOUS DISEASES | HOSPITALIZED-PATIENTS | ASIA-PACIFIC REGION | INITIAL ANTIBIOTIC-THERAPY | MICROBIOLOGY | INTRAABDOMINAL INFECTION | GRAM-NEGATIVE PATHOGENS | DISEASES-SOCIETY | IMIPENEM-CILASTATIN | PSEUDOMONAS-AERUGINOSA | PHARMACOLOGY & PHARMACY | BETA-LACTAMASE INHIBITOR | KLEBSIELLA-PNEUMONIAE | Imipenem - therapeutic use | Prospective Studies | Cilastatin - adverse effects | Humans | Middle Aged | Male | Gram-Negative Bacterial Infections - microbiology | Young Adult | Anti-Bacterial Agents - therapeutic use | Aged, 80 and over | Adult | Azabicyclo Compounds - therapeutic use | Female | Urinary Tract Infections - microbiology | Anti-Bacterial Agents - adverse effects | Cilastatin - therapeutic use | Pyelonephritis - drug therapy | Drug Therapy, Combination | Azabicyclo Compounds - adverse effects | Imipenem - administration & dosage | Double-Blind Method | Cilastatin - administration & dosage | Azabicyclo Compounds - administration & dosage | Gram-Negative Bacterial Infections - drug therapy | beta-Lactamase Inhibitors - administration & dosage | Urinary Tract Infections - drug therapy | Administration, Intravenous | beta-Lactamase Inhibitors - adverse effects | beta-Lactamase Inhibitors - therapeutic use | Adolescent | Aged | Anti-Bacterial Agents - administration & dosage | Drug Combinations | Imipenem - adverse effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Successful treatment of carbapenemase-producing pandrug-resistant Klebsiella pneumoniae bacteremia
by Camargo, Jose F and Simkins, Jacques and Beduschi, Thiago and Tekin, Akin and Aragon, Laura and Pérez-Cardona, Armando and Prado, Clara E and Morris, Michele I and Abbo, Lilian M and Cantón, Rafael
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 10/2015, Volume 59, Issue 10, pp. 5903 - 5908
New antibiotic options are urgently needed for the treatment of carbapenem-resistant Enterobacteriaceae infections. We report a 64-year-old female with... 
URINARY-TRACT-INFECTIONS | THERAPY | IMIPENEM | EFFICACY | BETA-LACTAMASE | CEFTAZIDIME-AVIBACTAM | BLOOD-STREAM | REGIMEN | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | OUTCOMES | ENTEROBACTERIACEAE | Klebsiella pneumoniae - drug effects | Klebsiella Infections - pathology | Humans | Immunosuppressive Agents - therapeutic use | Middle Aged | Minocycline - analogs & derivatives | Ganciclovir - analogs & derivatives | Colectomy | beta-Lactamases - biosynthesis | Intestine, Small - transplantation | Bacteremia - microbiology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Minocycline - therapeutic use | Drug Resistance, Multiple, Bacterial | Ganciclovir - therapeutic use | Azabicyclo Compounds - therapeutic use | Colistin - therapeutic use | Female | Thienamycins - therapeutic use | Klebsiella Infections - drug therapy | Antiviral Agents - therapeutic use | Intestine, Small - microbiology | Bacteremia - drug therapy | Trimethoprim, Sulfamethoxazole Drug Combination - therapeutic use | Klebsiella Infections - microbiology | Carbapenems - therapeutic use | Intestine, Small - drug effects | Klebsiella pneumoniae - enzymology | Klebsiella pneumoniae - growth & development | Bacterial Proteins - biosynthesis | Bacteremia - pathology | Ceftazidime - therapeutic use | Index Medicus | Challenging Clinical Cases in Antimicrobial Resistance
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Pharmaceutical Approaches to Target Antibiotic Resistance Mechanisms
by Schillaci, Domenico and Spanò, Virginia and Parrino, Barbara and Carbone, Anna and Montalbano, Alessandra and Barraja, Paola and Diana, Patrizia and Cirrincione, Girolamo and Cascioferro, Stella
Journal of Medicinal Chemistry, ISSN 0022-2623, 10/2017, Volume 60, Issue 20, pp. 8268 - 8297
There is urgent need for new therapeutic strategies to fight the global threat of antibiotic resistance. The focus of this Perspective is on chemical agents... 
PHTHALIC-ACID DERIVATIVES | CHEMISTRY, MEDICINAL | ANTIMICROBIAL DRUG SUSCEPTIBILITY | METALLO-BETA-LACTAMASE | NORA MULTIDRUG TRANSPORTER | EFFLUX PUMP INHIBITORS | PENICILLIN-BINDING PROTEINS | 6'-N-ACETYLTRANSFERASE TYPE IB | BACTERIAL BIOFILM FORMATION | IN-VITRO ACTIVITY | STANDARD NUMBERING SCHEME | Azabicyclo Compounds - pharmacology | Imipenem - therapeutic use | Drug Resistance, Microbial - drug effects | Pseudomonas Infections - drug therapy | Humans | beta-Lactamase Inhibitors - therapeutic use | Azabicyclo Compounds - therapeutic use | beta-Lactamase Inhibitors - pharmacology | Imipenem - pharmacology | Enterobacteriaceae Infections - drug therapy | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text The α7 nicotinic ACh receptor agonist compound B and positive allosteric modulator PNU‐120596 both alleviate inflammatory hyperalgesia and cytokine release in the rat
by Munro, G and Hansen, RR and Erichsen, HK and Timmermann, DB and Christensen, JK and Hansen, HH
British Journal of Pharmacology, ISSN 0007-1188, 09/2012, Volume 167, Issue 2, pp. 421 - 435
BACKGROUND AND PURPOSE Agonists selective for the α7 nicotinic acetylcholine (nACh) receptor produce anti‐hyperalgesic effects in rodent models of inflammatory... 
IL‐1β | pain | inflammation | carrageenan | TNF‐α | NSAID | analgesia | diclofenac | CFA | IL‐6 | TNF-α | IL-1β | IL-6 | Inflammation - chemically induced | Thiophenes - therapeutic use | Diclofenac - therapeutic use | Receptors, Nicotinic - metabolism | Freund's Adjuvant - toxicity | Cytokines - metabolism | Phenylurea Compounds - therapeutic use | Rats | Male | Rats, Sprague-Dawley | Gene Expression Regulation - drug effects | Inflammation - complications | Animals | Hyperalgesia - drug therapy | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Inflammation - drug therapy | Azabicyclo Compounds - therapeutic use | Isoxazoles - therapeutic use | Carrageenan - toxicity | Cytokines - genetics | alpha7 Nicotinic Acetylcholine Receptor | Index Medicus | Research Papers
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights